Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19

Thrombosis Research Institute (TRI)

2020/6/30 15:05

PR84565

 

LONDON, June 30, 2020 /PRNewswire=KYODO JBN/--

 

Clinical trial will recruit approximately 1400 patients in 10 countries

starting in July

 

Participants will be randomised to receive the low molecular weight Heparin

enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis

 

The study is supported through an investigator initiated grant from Sanofi

 

TRI will conduct an open-label randomized controlled trial of community-based

early thromboprophylaxis named ETHIC (Early Thromboprophylaxis in COVID-19).  

Eligible patients will have newly-diagnosed Covid-19 and also have been

identified with an increased risk of complications of infection due to age and

comorbidities.

 

The study was designed in response to recent evidence suggesting that severe

COVID-19 infections are associated with increased frequency of thrombosis.

 

Symptomatic patients with COVID-19 receiving the LMWH (via enoxaparin) will be

compared with patients receiving the standard of care. The follow up period for

assessing outcomes including hospitalization and mortality is at 21 days, with

further assessments at 50 days and 90 days.

 

Symptomatic COVID-19 patients receiving the LMWH (via enoxaparin) will be

compared with patients receiving the standard of care. The follow up period for

assessing outcomes including hospitalization and mortality is at 21 days, with

further assessments at 50 days and 90 days.

 

The study will be funded by an investigator-initiated study grant provided by Sanofi.

 

TRI Director Ajay Kakkar said: "Our understanding of the role of thrombosis and

anticoagulation in COVID-19 is rapidly evolving. We greatly appreciate the

opportunity to engage our global network of researchers in the evaluation of

anticoagulation in COVID-19 in the community setting for the first time. We are

immensely grateful to the colleagues and patients who will participate in this

important study."

 

The Thrombosis Research Institute is a leader in innovative solutions for the

detection and treatment of thrombosis. Sanofi is a global biopharmaceutical

company focused on improving human health.

 

Logo - https://mma.prnewswire.com/media/1195593/ETHIC_Logo.jpg

 

SOURCE: Thrombosis Research Institute (TRI)

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中